BIT Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

BIT Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,082	Closed	-$686K	–	106
2023 Q3	$686K	Sell	23,082 -22,277	-49%	-$459K	0.08%	64
2023 Q2	$817K	Buy	45,359 +5,297	+13%	+$106K	0.08%	79
2023 Q1	$643K	Buy	40,062 +17,925	+81%	+$332K	0.09%	80
2022 Q4	$405K	Sell	22,137 -8,049	-27%	-$142K	0.08%	92
2022 Q3	$593K	Buy	+30,186	New	+$616K	0.11%	58
2022 Q2	–	Sell	-9,500	Closed	-$209K	–	126
2022 Q1	$209K	Buy	+9,500	New	+$192K	0.02%	93

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BIT Capital's CRNX Position: Q4 2023 in Review

BIT Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 23,082 shares — an estimated $686K sold.

BIT Capital first reported a position in CRNX in Q1 2022 and held it in 6 quarters. The position peaked at $817K in Q2 2023. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

BIT Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
BIT Capital sold 23,082 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $686K.
BIT Capital first reported a position in Crinetics Pharmaceuticals in Q1 2022 and held it in 6 quarters.
BIT Capital's Crinetics Pharmaceuticals position peaked at $817K in Q2 2023.
181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on BIT Capital's 13F filing for Q4 2023, filed 12 Feb 2025.